Unilife — Investor Presentation (February 2010)
22 slides from Unilife's investor presentation, Feb 17, 2010

Slide 1: An emerging global leader for innovative safety medical devices
An emerging global leader for innovative safety medical devices February 2010

Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements

Slide 3: Business Overview
Well positioned to succeed in fast-growing healthcare & pharmaceutical markets being driven to mandatory use First range of prefilled & clinical syringes with a technology platform of automatic, fully integrated safety features Sanofi-aventis (largest prefilled syringe purchaser) paying $40m for Uni

Slide 4: The Global Transition to Safety Syringes
The Global Transition to Safety Syringes 1.3m^ people die annually from unsafe injection practices Needlestick injuries a serious threat to healthcare workers US mandates and enforces safety syringes within facilities Europe and other international markets now following Pharmaceutical companies must

Slide 5: Portfolio of Best-in-Class Safety Syringes
Portfolio of Best-in-Class Safety Syringes Key proprietary features: Automatic needle retraction Operator controls speed of needle retraction from body into the barrel Auto-disable (anti-tampering) Fully integrated within barrel Virtually eliminates infection risk from needlestick injuries or aeroso

Slide 6: Unilife Brand Architecture
Unilife Brand Architecture Ready-to-Fill (Prefilled) syringes (glass barrel) Supplied to pharmaceutical companies Clinical syringes (plastic barrel for use with vials) Supplied for use by healthcare workers and self-injecting patients (i.e. insulin)

Slide 7: Key Target Markets
Key Target Markets Targeting fast-growing and non-crowded markets that are pre-conditioned to demand premium safety devices Unilife Target Market Volumes^ (billions) Annual Growth Rate Capacity For Premium Devices Market Transition to Safety Level of Comp. Pharmaceutical High 2.7 High High Mature Lo

Slide 8: Pharmaceutical Market for Prefilled Syringes
Pharmaceutical Market for Prefilled Syringes More than 2.7* billion prefilled syringes used globally $1.5** billion market growing at more than 15% annually 50+ injectable drugs and vaccines are now prefilled Market now restricted to attaching ancillary safety devices to standard prefilled syringes

Slide 9: Agreements with sanofi-aventis
Agreements with sanofi-aventis Long-term relationship with 'top 5' pharmaceutical leader Exclusive Agreement signed in July 2008 €10m fee for exclusive right to negotiate Unifill(tm) purchase Agreed to start and fund the industrialization program Industrialization Agreement signed in June 2009 Commi

Slide 10: The Unifill Syringe
The world's first true prefilled safety syringe Insertion into standard prefilled fill-finish systems Use of proven materials for components in fluid path All safety features fully integrated inside glass barrel Streamlines filling and packaging processes Compact in size for easy handling & convenie

Slide 11: Unifill is the only primary syringe container with safety mechanism inside the glass barrel
Unifill(tm) is the only primary syringe container with safety mechanism inside the glass barrel Competitive Position Unifill (tm) syringes Glass Prefilled Syringe Fully Integrated External Sheath Controlled Retraction into Barrel Active Activation Needle Guard Passive Activation Stand - - Alone Need

Slide 12: Ancillary Safety Products Attached onto Standard Prefilled Syringes
Ancillary Safety Products Attached onto Standard Prefilled Syringes Unifill syringe Ancillary Safety Products Attached onto Standard Prefilled Syringes The Unifill(tm) Syringe Competitive Comparison

Slide 13: Unifill Industrialization program
Unifill(tm) Industrialization program Commenced in July 2008 Target completion late 2010 Mikron engaged for assembly Assembly process validated 60m / year assembly line ready late 2010 Further assembly lines to have 150m per year capacity

Slide 14: Unitract Range of 1mL Syringes
Unitract(tm) Range of 1mL Syringes Target markets include Healthcare facilities Diabetes / home-injection Harm reduction Insulin, TB and Safe variants FDA and CE Mark certified* US production commenced * Certification applies to product manufactured in China. US certification pending

Slide 15: Positioning Unilife for Success
ISO-13485 certified with FDA-registered facilities in PA Team of more than 120 world-class staff Strong patent position for our proprietary products Strong cash position, multiple funding / revenue streams Successfully redomiciled from Australia to the US NASDAQ listing supports ongoing expansion ac

Slide 16: New Global Headquarters and Production Center
Positioning Unilife for Success New Global Headquarters and Production Center State-of-the-art facility to meet highest industry standards Stage one capacity supports 400 million syringes a year 2nd stage approval supports production of 1 billion units Ready for operations in late 2010

Slide 17: Additional pharmaceutical relationships
Positioning Unilife for Success Additional pharmaceutical relationships

Slide 18: Development of Pipeline Products
Positioning Unilife for Success Glass ready-to-fill Unifill(tm) Select Attachable needles Plastic for vial Unitract Clinical Range 3 & 5mL with Luer needle Development of Pipeline Products

Slide 19: Strong Product Pipeline
Strong Product Pipeline Current 2010-2011 2012 + Unifill(tm) Select attachable needles^ Unitract(tm) 3 & 5mL with luer needle Unifill(tm) syringe with fixed needle Unitract(tm) 1mL Insulin, TB and Safe ^ subject to securing agreement with an interested pharmaceutical party

Slide 20: Background Financial Data
Background Financial Data Selected Data Strong cash position $41.4m (as of 12/31/09) $14m from sanofi-aventis in 2008, regular milestone payments Raised approx $47.5m in US / Australian markets Nov. 2009 Secured $5.2m package from PA Government in Oct. 2009 Cap. Structure Approx 50m shares of common

Slide 21: Upcoming Milestones
Upcoming Milestones Commercial release of US-made Unitract(tm) 1mL syringes Completion of negotiations for Unifill(tm) exclusivity list Listing on NASDAQ Open new global headquarters and production facility in PA Completion of Unifill(tm) industrialization program Agreements with additional pharmace

Slide 22: Summary
Summary Unifill(tm) syringe represents 'disruptive technology' World's major prefilled buyer committed $40m^ (pre-sales) Industry certified with FDA-registered production facilities Strong cash position, multiple funding & revenue streams Well-positioned to attain strong market share in the pharmace
Source: SEC EDGAR · 8-K filed Feb 17, 2010
More decks from Unilife Corp
Investor Presentation (November 2016)13 slides · Nov 17, 2016
Q4 and FY2016 Earnings Presentation19 slides · Nov 2, 2016
Earnings Presentation (July 2015)23 slides · Jul 30, 2015
Q2 FY2015 Earnings Presentation15 slides · Feb 12, 2015
Piper Jaffray Healthcare Conference 201415 slides · Dec 2, 2014
Q1 FY2015 Earnings Presentation12 slides · Nov 14, 2014